Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound will start IND enabling studies the second quarter 2019.
News
Medibiofarma announces the nomination of a second Development Candidate
0
Related News
0
MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-015 PHASE I CLINICAL STUDY: New HDAC1/2 inhibitor in healthy volunteers
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No Comments
0
Medibiofarma announces first subject dosed in phase Ib multiple ascending dose study of MBF-118, a new PPARg covalent partial agonist, in healthy volunteers
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No Comments
0
MEDIBIOFARMA ANNOUNCES FIRST SUBJECT DOSED IN MBF-118 CLINICAL STUDY: New PPARg covalent partial agonist in healthy volunteers
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No Comments
0
Medibiofarma participated in the “Startup Spotlight” event of the annual BIO-Europe Spring conference held on March 26, 2019 in Vienna, Austria
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No Comments
2
Medibiofarma announced the nomination of a new Development Candidate
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No Comments
0
MEDIBIOFARMA announced the first patient dosed in the Phase IIa clinical trial of MBF-118 in patients with Crohn’s disease.
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No Comments
0
Medibiofarma Receives Funding from the Crohn’s & Colitis Foundation to Support Development of a New Antifibrotic Therapy for Inflammatory Bowel Disease
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No Comments
0
Medibiofarma announces the completion of a new financing round
Compound MBF-251, a novel EP2/EP4 dual antagonist for the treatment of cancer. The compound...
No Comments